Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05957549
Other study ID # K23HD109375
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 4, 2022
Est. completion date August 31, 2027

Study information

Verified date July 2023
Source Children's Hospital Medical Center, Cincinnati
Contact Elizabeth Smith, PhD
Phone 5135171383
Email elizabeth.smith3@cchmc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Individuals with Fragile X Syndrome show differences in how they understand and learn language from infancy. They frequently have lifelong delays in speech and language as well. In addition, they experience other auditory symptoms, including being very sensitive to certain sounds as well as being more sensitive than others to loud sounds. The underlying brain activity for sound perception and speech learning in Fragile X is not well understood, especially in the infant and toddler years. This study uses behavioral assessment of speech and language abilities, neuroimaging, and hearing tests to understand how speech and hearing are different in children with Fragile X Syndrome.


Description:

Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism and is associated with extremely high risk for early delays in speech and language. While the infant years are essential to speech and language development, neural mechanisms for language impairments have been studied entirely in older children and adults with FXS. Therefore, markers for speech and language impairments are unavailable in infants and young children with FXS to predict severity, test potential mechanisms, and track response to intervention. The investigators have identified a hallmark brain-based phenotype of hyperresponsiveness to sounds in adolescents and adults with FXS. This fundamental alteration in cortical responses to sound could influence early language delays, but this phenotype has not been explored in infants or toddlers with FXS. Specifically, in this study the investigators will use simultaneous EEG/fNIRS during presentation of simple speech, stories, and nonspeech sounds to quantify and localize auditory hypersensitivity and neural differentiation in 30 preschoolers with FXS. The investigators will assess specificity through comparison with 30 typically developing controls and 30 mental-age matched children with a history of premature birth and language delays. In addition, the investigators will complete a longitudinal study (3 timepoints) of 15 infants with FXS and 15 TDC controls, with the first visit completed between 6 and 12 months of age. At each visit, the investigators will measure speech and hearing alongside cortical responses to sounds. In combination with quantitative assessment of linguistic complexity in each infant's home environment, the investigators will develop a potential model linking brain-based indicators with emergence of language delays in FXS


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date August 31, 2027
Est. primary completion date September 1, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 5 Years
Eligibility Inclusion Criteria: - Diagnoses of Fragile X Syndrome, Typical Development, or History of Premature Birth - able to sit independently - English is spoken at home Exclusion Criteria: - For all participants: no seizures in the past 6 months - For typical development group and Fragile X group: not born prior to 36 weeks gestation

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Speech discrimination
Two different speech sounds are played at the same sound intensity.

Locations

Country Name City State
United States Cincinnati Children'S Hospital Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Mullen Scales of Early Learning change in Mullen Scales scores (age-corrected) from baseline on all subscales, including Expressive Language, Receptive Language, FIne Motor, Gross Motor, and Visual Reception. T-Scores from the Mullen Scales of Early Learning (MSEL) have a mean of 50 and a standard deviation of 10. Range=20-80. Higher scores indicate more advanced developmental skills. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Primary Changes in oxygenated and deoxygenated hemoglobin concentration in response to sounds in language regions of the brain Relative increase in oxygenated versus deoxygenated hemoglobin for no sounds, low intensity sounds, and medium intensity sounds. Measured via functional Near Infrared Spectroscopy with optodes placed over frontal, temporal, and parietal language regions. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Primary Changes in amplitude of mismatch negativity response during sound discrimination Electroencephalography is measured over the scalp while participant listens to speech sounds with infrequent "oddball" stimuli. Amplitude of the P100 for all stimuli as well as amplitude of the mismatch negativity response (frequent minus infrequent response) as well as change in these metrics over development are tracked in all groups. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Primary Changes in LENA vocalizations and conversational turns LENA is a voice recording system and proprietary program that records a child's home language environment and quantifies number of sounds and words each child produces as well as complexity of home language environment via number of conversational turns between the child and parents. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Primary Changes in hearing thresholds Hearing thresholds in dB as assessed using Conditioned Play Audiometry (CPA) or Visual Reinforced Audiometry (VRA) dependent on child age and developmental ability. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Primary Otoacoustic Emissions (OAEs) Signals produced by excitation of hair cells in cochlea are measured for a range of frequencies. At first study visit
Primary Changes in tympanometric pressure profile in the inner ear Wide Band Tympanometry is completed to measure variability in tympanometric pressure for left and right ears that may affect hearing profile. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Secondary Sensory profile 2 Auditory Processing subtest parent-report measure of child's behavioral responses to sounds in their environment at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
Secondary Sensory Profile 2 Attentional subtest parent-report measure of child's awareness of and responses to sensory cues in their environment. at 6 month, 12 month, 18 month, 24 month, 3 year, and 4 year visits
See also
  Status Clinical Trial Phase
Recruiting NCT05418049 - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT00965432 - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 Phase 1
Completed NCT01120626 - Randomized Controlled Study of Donepezil in Fragile X Syndrome Phase 2
Completed NCT01204151 - Teaching Math Skills to Individuals With Fragile X Syndrome N/A
Active, not recruiting NCT00334971 - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT04977986 - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome Phase 3
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT03722290 - Metformin in Children and Adults With Fragile X Syndrome Phase 2
Completed NCT05030129 - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome Phase 2
Recruiting NCT04141163 - Metformin in Patients With Fragile X Phase 1/Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT00858689 - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Enrolling by invitation NCT03802799 - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Phase 2/Phase 3
Recruiting NCT05295277 - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome Phase 2
Terminated NCT01433354 - Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) Phase 2/Phase 3